Tag

Pan-RAS

2 stories

RevMed Doubles Phase 3 Survival With Pan-RAS Drug at AACR25

Revolution Medicines' pan-RAS inhibitor delivered a landmark Phase 3 survival readout at AACR25 that doubled survival, setting off what the oncology field…

FDA Apr 13, 2026

Cleared Phase 3: Daraxonrasib Hits 13.2-Month OS in Pancreatic Cancer

Daraxonrasib cleared both primary endpoints in a phase 3 trial for previously treated metastatic pancreatic cancer, Revolution Medicines reported April 13.